

**Addressing Knowledge Gaps in the Diagnostic Process and Outpatient Treatment of COVID-19:
Updating Clinicians on Current Best Practices in 2022**

Resource	Address
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4). Clinicaltrials.gov identifier: NCT 04634409. Updated July 1, 2022.	https://clinicaltrials.gov/ct2/show/NCT04634409
Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants - clinical, public health, and vaccine implications. <i>N Engl J Med</i> . 2021;384(19):1866-1868.	https://pubmed.ncbi.nlm.nih.gov/33761203/
Agency for Healthcare Research and Quality (AHRQ). The CAHPS Ambulatory Care Improvement Guide: Practical Strategies for Improving Patient Experience. December 2017.	https://www.ahrq.gov/sites/default/files/wysiwyg/cahps/quality-improvement/improvement-guide/cahps-ambulatory-care-guide-full.pdf
Agency for Healthcare Research and Quality (AHRQ). The SHARE Approach. Essential Steps of Shared Decisionmaking: Quick Reference Guide. April 2014.	https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/education/curriculum-tools/shareddecisionmaking/tools/tool-1/share-tool1.pdf
Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. <i>J Infect Dis</i> . 2021;223(1):23-27.	https://pubmed.ncbi.nlm.nih.gov/33089317/
Bierle DM, Ganesh R, Wilker CG, et al. Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19. <i>J Prim Care Community Health</i> . 2021;12:21501327211019282.	https://pubmed.ncbi.nlm.nih.gov/34032171/
CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. <i>MMWR Morb Mortal Wkly Rep</i> . 2020;69(12):343-346.	https://pubmed.ncbi.nlm.nih.gov/32214079/
Centers for Disease Control and Prevention. Clinical Course: Progression, Management, and Treatment. Clinical considerations for care of children and adults with confirmed COVID-19. Updated December 5, 2022.	www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/clinical-considerations-course.html
Centers for Disease Control and Prevention. Clinical Presentation. Clinical considerations for care of children and adults with confirmed COVID-19. Updated October 19, 2022.	www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/clinical-considerations-presentation.html
Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. <i>BMJ</i> . 2020;371:m3862.	https://pubmed.ncbi.nlm.nih.gov/33097561/
Cheng A, Caruso D, McDougall C. Outpatient management of COVID-19: Rapid evidence review. <i>Am Fam Physician</i> . 2020;102(8):478-486.	https://pubmed.ncbi.nlm.nih.gov/33064422/

Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic testing for severe acute respiratory syndrome-related coronavirus 2: A narrative review. <i>Ann Intern Med.</i> 2020;172(11):726-734.	https://pubmed.ncbi.nlm.nih.gov/32282894/
Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. <i>N Engl J Med.</i> 2020;383(23):2291-2293.	https://pubmed.ncbi.nlm.nih.gov/33176080/
Danis K, Epaulard O, Bénet T, et al. Cluster of coronavirus disease 2019 (COVID-19) in the French Alps, February 2020. <i>Clin Infect Dis.</i> 2020;71(15):825-832.	https://pubmed.ncbi.nlm.nih.gov/32277759/
Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv 2022.03.10.22272100.	https://www.medrxiv.org/content/10.1101/2022.03.10.22272100v1.full
Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: A population-based cohort study. <i>Ann Intern Med.</i> 2023;176(1):77-84.	https://pubmed.ncbi.nlm.nih.gov/36508742/
Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. <i>N Engl J Med.</i> 2020;383(18):1757-1766.	https://pubmed.ncbi.nlm.nih.gov/32329974/
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. <i>N Engl J Med.</i> 2022;386(4):305-315.	https://pubmed.ncbi.nlm.nih.gov/34937145/
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. <i>N Engl J Med.</i> 2022;386(15):1397-1408.	https://pubmed.ncbi.nlm.nih.gov/35172054/
Hamner L, Dubbel P, Capron I, et al. High SARS-CoV-2 attack rate following exposure at a choir practice - Skagit County, Washington, March 2020. <i>MMWR Morb Mortal Wkly Rep.</i> 2020;69(19):606-610.	https://pubmed.ncbi.nlm.nih.gov/32407303/
Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. <i>JAMA.</i> 2016;316(23):2547-2548.	https://pubmed.ncbi.nlm.nih.gov/27792809/
Hensley MK, Bain WG, Jacobs J, et al. Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: A case study. <i>Clin Infect Dis.</i> 2021;73(3):e815-e821.	https://pubmed.ncbi.nlm.nih.gov/33507235/
Hijnen D, Marzano AV, Eyerich K, et al. SARS-CoV-2 transmission from presymptomatic meeting attendee, Germany. <i>Emerg Infect Dis.</i> 2020;26(8):1935-1937.	https://pubmed.ncbi.nlm.nih.gov/32392125/
Imam Z, Odish F, Gill I, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. <i>J Intern Med.</i> 2020;288(4):469-476.	https://pubmed.ncbi.nlm.nih.gov/32498135/

Infectious Diseases Society of America. COVID-19 Real-Time Learning Network. Anti-SARS-CoV-2 Monoclonal Antibodies. Last reviewed December 20, 2022	https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-interventions/monoclonal-antibodies/
Infectious Diseases Society of America. COVID-19 Real-Time Learning Network. COVID-19 Outpatient Treatment Guidelines Roadmap. Updated June 21, 2022.	www.idsociety.org/globalassets/covid-19-real-time-learning-network/outpatientroadmap-v10.pdf
Infectious Diseases Society of America. COVID-19 Real-Time Learning Network. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Last updated November 21, 2022.	https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
Infectious Diseases Society of America. COVID-19 Real-Time Learning Network. Rapid Testing. Last reviewed: September 6, 2022.	https://www.idsociety.org/covid-19-real-time-learning-network/diagnostics/rapid-testing/#
Jayk BA, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. <i>N Engl J Med.</i> 2022;386(6):509-520.	https://pubmed.ncbi.nlm.nih.gov/34914868/
Lamers MM, Mykytyn AZ, Breugem TI, et al. SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium. <i>bioRxiv.</i> 2022:2022.01.19.476898.	https://www.biorxiv.org/content/10.1101/2022.01.19.476898v1
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. <i>N Engl J Med.</i> 2020;382(13):1199-1207.	https://pubmed.ncbi.nlm.nih.gov/31995857/
Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID study. <i>Lancet.</i> 2022;399(10335):1618-1624.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00327-0/fulltext
Merck Sharp & Dohme LLC. Fact sheet for healthcare providers: emergency use authorization for Lagevrio™ (molnupiravir) capsules. Revised August 2022.	https://www.fda.gov/media/155054/download
National Institutes of Health (NIH). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Updated: January 10, 2023.	https://www.covid19treatmentguidelines.nih.gov/
National Institutes of Health. General Management of Nonhospitalized Adults With Acute COVID-19. Updated September 26, 2022.	https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults-general-management/
Ng WH, Tipih T, Makoah NA, et al. Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis. <i>mBio.</i> 2021;12(1):e03647-20.	https://pubmed.ncbi.nlm.nih.gov/33563817/
Ogunwole SU, Rabe MA, Roberts AW, Caplan Z. US Census Bureau. U.S. Adult Population Grew Faster Than Nation's Total Population From 2010 to 2020. August 12, 2021	www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html

Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. <i>Lancet Infect Dis</i> . 2020;20(4):411-412.	https://pubmed.ncbi.nlm.nih.gov/32105638/
RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. <i>Lancet</i> . 2020;396(10259):1345-1352.	https://pubmed.ncbi.nlm.nih.gov/33031764/
Rommasi F, Nasiri MJ, Mirsaiedi M. Antiviral drugs proposed for COVID-19: Action mechanism and pharmacological data. <i>Eur Rev Med Pharmacol Sci</i> . 2021;25(11):4163-4173.	https://pubmed.ncbi.nlm.nih.gov/34156698/
Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity of COVID-19 in South Korea. <i>Int J Infect Dis</i> . 2020;93:339-344.	https://pubmed.ncbi.nlm.nih.gov/32198088/
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. <i>J Heart Lung Transplant</i> . 2020;39(5):405-407.	https://pubmed.ncbi.nlm.nih.gov/32362390/
Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. <i>MMWR Morb Mortal Wkly Rep</i> . 2020;69(24):759-765.	https://pubmed.ncbi.nlm.nih.gov/32555134/
Tartof SY, Qian L, Hong V, et al. Obesity and mortality among patients diagnosed with COVID-19: Results from an integrated health care organization. <i>Ann Intern Med</i> . 2020;173(10):773-781.	https://pubmed.ncbi.nlm.nih.gov/32783686/
University of Liverpool. COVID-19 drug interactions. 2023.	https://www.covid19-druginteractions.org/checker
US Centers for Disease Control and Prevention. How COVID spreads. Updated August 11, 2022.	https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html
US Centers for Disease Control and Prevention. People with Certain Medical Conditions. Updated December 6, 2022.	https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
Veklury® (remdesivir). Prescribing information. Gilead Sciences, Inc; December 2022.	https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. <i>JAMA</i> . 2020;323(11):1061-1069.	https://pubmed.ncbi.nlm.nih.gov/32031570/
WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of the WHO Solidarity randomised trial and updated meta-analyses. <i>Lancet</i> . 2022;399(10339):1941-1953.	https://pubmed.ncbi.nlm.nih.gov/35512728/
Williams V. What does supportive care mean for patients with COVID-19? <i>Mayo Clinic News Network</i> . March 26, 2020.	https://newsnetwork.mayoclinic.org/discussion/what-does-supportive-care-mean-for-patients-with-covid-19/

Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. <i>Nature</i> . 2020;584(7821):430-436.	https://pubmed.ncbi.nlm.nih.gov/32640463/
Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. <i>Nature</i> . 2020;581(7809):465-469.	https://pubmed.ncbi.nlm.nih.gov/32235945/
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. <i>JAMA</i> . 2020;323(13):1239-1242.	https://pubmed.ncbi.nlm.nih.gov/32091533/
Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. <i>N Engl J Med</i> . 2020;383(13):1283-1286.	https://pubmed.ncbi.nlm.nih.gov/32857487/
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. <i>Lancet</i> . 2020;395(10229):1054-1062.	https://pubmed.ncbi.nlm.nih.gov/32171076/
Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. <i>N Engl J Med</i> . 2020;382(12):1177-1179.	https://pubmed.ncbi.nlm.nih.gov/32074444/